Skip Header

 
Contribute Send feedback
Read comments (1) or add your own

Reviewed, UniProtKB/Swiss-Prot P15498 (VAV_HUMAN)

Last modified June 16, 2009. Version 119. Feed History...

Clusters with 100%, 90%, 50% identity | Documents (6) | Third-party data | Customize display text xml rdf/xml gff fasta
Names and origin · Protein attributes · General annotation (Comments) · Ontologies · Binary interactions · Sequence annotation (Features) · Sequences · References · Web resources · Cross-references · Entry information · Relevant documents

Names and origin

Protein namesRecommended name:
    Proto-oncogene vav
Gene names
Name: VAV1
Synonyms: VAV
OrganismHomo sapiens (Human)
Taxonomic identifier9606 [NCBI]
Taxonomic lineageEukaryotaMetazoaChordataCraniataVertebrataEuteleostomiMammaliaEutheriaEuarchontogliresPrimatesHaplorrhiniCatarrhiniHominidaeHomo

Protein attributes

Sequence length845 AA.
Sequence statusComplete.
Sequence processingThe displayed sequence is not processed.
Protein existenceEvidence at protein level.

General annotation (Comments)

Function

Couples tyrosine kinase signals with the activation of the Rho/Rac GTPases, thus leading to cell differentiation and/or proliferation.

Subunit structure

May interact with CCPG1 By similarity. Interacts with APS, DOCK2, GRB2, GRB3, DOCK2, SLA and ZNF655/VIK. Interacts with SIAH2; without leading to its degradation. Associates with BLNK, PLCG1, GRB2 and NCK1 in a B-cell antigen receptor-dependent fashion. Interacts with CBLB; which inhibits tyrosine phosphorylation and down-regulates activity. Interacts with SHB and CLNK By similarity.

Tissue specificity

Widely expressed in hematopoietic cells but not in other cell types.

Domain

The DH domain is involved in interaction with CCPG1 By similarity.

Post-translational modification

Phosphorylated on tyrosine residues. Ref.14

Miscellaneous

'Vav' stands for the sixth letter of the Hebrew alphabet.

Sequence similarities

Contains 1 CH (calponin-homology) domain.

Contains 1 DH (DBL-homology) domain.

Contains 1 PH domain.

Contains 1 phorbol-ester/DAG-type zinc finger.

Contains 1 SH2 domain.

Contains 2 SH3 domains.

Sequence caution

The sequence CAA34383.1 differs from that shown. Reason: Frameshift at positions 322 and 355.

Binary interactions

With

Entry

#Exp.

IntAct

Notes

GRB2P629931EBI-625518,EBI-401755
ZNF655Q8N7204EBI-625518,EBI-625509

Sequence annotation (Features)

Feature keyPosition(s)LengthDescriptionGraphical viewFeature identifier

Molecule processing

Chain1 – 845845Proto-oncogene vav
PRO_0000080980

Regions

Domain1 – 119119CH
Domain194 – 373180DH
Domain402 – 504103PH
Domain617 – 66044SH3 1
Domain671 – 76595SH2
Domain782 – 84261SH3 2
Zinc finger515 – 56450Phorbol-ester/DAG-type
Compositional bias33 – 9967Leu-rich

Amino acid modifications

Modified residue8261Phosphotyrosine Ref.14
Modified residue8441Phosphotyrosine By similarity

Natural variations

Natural variant7391T → M: dbSNP rs36097961.
VAR_051997

Experimental info

Mutagenesis5291C → R: Abolishes transforming activity. Ref.1
Sequence conflict2641A → P in CAA34383. Ref.4
Sequence conflict7181I → TV Ref.4

Secondary structure

.............................................................................. 845
Helix Strand Turn

Details...

Sequences

Sequence LengthMass (Da)Tools
P15498-1 [UniParc].

Last modified February 21, 2001. Version 4.
Checksum: AC3BC9736FD2F138

FASTA84598,314
        10         20         30         40         50         60 
MELWRQCTHW LIQCRVLPPS HRVTWDGAQV CELAQALRDG VLLCQLLNNL LPHAINLREV 

        70         80         90        100        110        120 
NLRPQMSQFL CLKNIRTFLS TCCEKFGLKR SELFEAFDLF DVQDFGKVIY TLSALSWTPI 

       130        140        150        160        170        180 
AQNRGIMPFP TEEESVGDED IYSGLSDQID DTVEEDEDLY DCVENEEAEG DEIYEDLMRS 

       190        200        210        220        230        240 
EPVSMPPKMT EYDKRCCCLR EIQQTEEKYT DTLGSIQQHF LKPLQRFLKP QDIEIIFINI 

       250        260        270        280        290        300 
EDLLRVHTHF LKEMKEALGT PGAANLYQVF IKYKERFLVY GRYCSQVESA SKHLDRVAAA 

       310        320        330        340        350        360 
REDVQMKLEE CSQRANNGRF TLRDLLMVPM QRVLKYHLLL QELVKHTQEA MEKENLRLAL 

       370        380        390        400        410        420 
DAMRDLAQCV NEVKRDNETL RQITNFQLSI ENLDQSLAHY GRPKIDGELK ITSVERRSKM 

       430        440        450        460        470        480 
DRYAFLLDKA LLICKRRGDS YDLKDFVNLH SFQVRDDSSG DRDNKKWSHM FLLIEDQGAQ 

       490        500        510        520        530        540 
GYELFFKTRE LKKKWMEQFE MAISNIYPEN ATANGHDFQM FSFEETTSCK ACQMLLRGTF 

       550        560        570        580        590        600 
YQGYRCHRCR ASAHKECLGR VPPCGRHGQD FPGTMKKDKL HRRAQDKKRN ELGLPKMEVF 

       610        620        630        640        650        660 
QEYYGLPPPP GAIGPFLRLN PGDIVELTKA EAEQNWWEGR NTSTNEIGWF PCNRVKPYVH 

       670        680        690        700        710        720 
GPPQDLSVHL WYAGPMERAG AESILANRSD GTFLVRQRVK DAAEFAISIK YNVEVKHIKI 

       730        740        750        760        770        780 
MTAEGLYRIT EKKAFRGLTE LVEFYQQNSL KDCFKSLDTT LQFPFKEPEK RTISRPAVGS 

       790        800        810        820        830        840 
TKYFGTAKAR YDFCARDRSE LSLKEGDIIK ILNKKGQQGW WRGEIYGRVG WFPANYVEED 


YSEYC 

« Hide

References

« Hide 'large scale' references
[1]"Mechanism of activation of the vav protooncogene."
Coppola J., Bryant S., Koda T., Conway D., Barbacid M.
Cell Growth Differ. 2:95-105(1991) [PubMed: 2069873] [Abstract]
Cited for: NUCLEOTIDE SEQUENCE [MRNA], MUTAGENESIS OF CYS-529.
[2]"Genomic organization and regulation of the vav proto-oncogene."
Denkinger D.J., Borges C.R., Butler C.L., Cushman A.M., Kawahara R.S.
Biochim. Biophys. Acta 1491:253-262(2000) [PubMed: 10760587] [Abstract]
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA].
[3]"Loss of the amino-terminal helix-loop-helix domain of the vav proto-oncogene activates its transforming potential."
Katzav S., Cleveland J.L., Heslop H.E., Pulido D.
Mol. Cell. Biol. 11:1912-1920(1991) [PubMed: 2005887] [Abstract]
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-61.
[4]"vav, a novel human oncogene derived from a locus ubiquitously expressed in hematopoietic cells."
Katzav S., Martin-Zanca D., Barbacid M.
EMBO J. 8:2283-2290(1989) [PubMed: 2477241] [Abstract]
Cited for: NUCLEOTIDE SEQUENCE [MRNA] OF 68-845.
[5]Romero F.
Submitted (JAN-1995) to the EMBL/GenBank/DDBJ databases
Cited for: NUCLEOTIDE SEQUENCE [MRNA] OF 299-837.
[6]"The proline-rich region of Vav binds to Grb2 and Grb3-3."
Ramos-Morales F., Romero F., Schweighoffer F., Bismuth G., Camonis J., Tortolero M., Fischer S.
Oncogene 11:1665-1669(1995) [PubMed: 7478592] [Abstract]
Cited for: NUCLEOTIDE SEQUENCE [MRNA] OF 299-334.
[7]"The hematopoietically expressed vav proto-oncogene shares homology with the dbl GDP-GTP exchange factor, the bcr gene and a yeast gene (CDC24) involved in cytoskeletal organization."
Adams J.M., Houston H., Allen J., Lints T., Harvey R.
Oncogene 7:611-618(1992) [PubMed: 1565462] [Abstract]
Cited for: SIMILARITY TO CDC24 FAMILY.
[8]"Cbl-b, a member of the Sli-1/c-Cbl protein family, inhibits Vav-mediated c-Jun N-terminal kinase activation."
Bustelo X.R., Crespo P., Lopez-Barahona M., Gutkind J.S., Barbacid M.
Oncogene 15:2511-2520(1997) [PubMed: 9399639] [Abstract]
Cited for: INTERACTION WITH CBLB.
[9]"BLNK: a central linker protein in B cell activation."
Fu C., Turck C.W., Kurosaki T., Chan A.C.
Immunity 9:93-103(1998) [PubMed: 9697839] [Abstract]
Cited for: INTERACTION WITH BLNK; PLCG1; GRB2 AND NCK1.
[10]"hSiah2 is a new Vav binding protein which inhibits Vav-mediated signaling pathways."
Germani A., Romero F., Houlard M., Camonis J., Gisselbrecht S., Fischer S., Varin-Blank N.
Mol. Cell. Biol. 19:3798-3807(1999) [PubMed: 10207103] [Abstract]
Cited for: INTERACTION WITH SIAH2.
[11]"DOCK2 associates with CrkL and regulates Rac1 in human leukemia cell lines."
Nishihara H., Maeda M., Oda A., Tsuda M., Sawa H., Nagashima K., Tanaka S.
Blood 100:3968-3974(2002) [PubMed: 12393632] [Abstract]
Cited for: INTERACTION WITH DOCK2.
[12]"Shb links SLP-76 and Vav with the CD3 complex in Jurkat T cells."
Lindholm C.K., Henriksson M.L., Hallberg B., Welsh M.
Eur. J. Biochem. 269:3279-3288(2002) [PubMed: 12084069] [Abstract]
Cited for: INTERACTION WITH SHB.
[13]"Adaptor protein APS binds the NH2-terminal autoinhibitory domain of guanine nucleotide exchange factor Vav3 and augments its activity."
Yabana N., Shibuya M.
Oncogene 21:7720-7729(2002) [PubMed: 12400014] [Abstract]
Cited for: INTERACTION WITH APS.
[14]"Immunoaffinity profiling of tyrosine phosphorylation in cancer cells."
Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H., Zha X.-M., Polakiewicz R.D., Comb M.J.
Nat. Biotechnol. 23:94-101(2005) [PubMed: 15592455] [Abstract]
Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-826, MASS SPECTROMETRY.
[15]"Characterization of VIK-1: a new Vav-interacting Kruppel-like protein."
Houlard M., Romero-Portillo F., Germani A., Depaux A., Regnier-Ricard F., Gisselbrecht S., Varin-Blank N.
Oncogene 24:28-38(2005) [PubMed: 15558030] [Abstract]
Cited for: INTERACTION WITH ZNF655/VIK.
[16]Colinge J., Superti-Furga G., Bennett K.L.
Submitted (OCT-2008) to UniProtKB
Cited for: IDENTIFICATION [LARGE SCALE ANALYSIS], MASS SPECTROMETRY.
[17]"Solution structure of the SH2 domain of human proto-oncogene protein VAV1."
RIKEN structural genomics initiative (RSGI)
Submitted (NOV-2005) to the PDB data bank
Cited for: STRUCTURE BY NMR OF 661-775.
+Additional computationally mapped references.

Cross-references

Sequence databases

AF030227 expand/collapse EMBL AC list , AF030201, AF030202, AF030203, AF030204, AF030205, AF030206, AF030207, AF030208, AF030209, AF030210, AF030211, AF030212, AF030213, AF030214, AF030215, AF030216, AF030217, AF030218, AF030219, AF030220, AF030221, AF030222, AF030223, AF030224, AF030225, AF030226 Genomic DNA. Translation: AAC25011.1.
M59834 Genomic DNA. Translation: AAA63267.1.
X16316 mRNA. Translation: CAA34383.1. Frameshift.
X83931 mRNA. Translation: CAA58783.1.
IPIIPI00011696.
PIRTVHUVV. B39576.
RefSeqNP_005419.2.
UniGeneHs.116237

3D structure databases

EntryMethodResolution (Å)ChainPositionsPDBsum
2CRHNMR-A629-775[»]
2RORNMR-A629-775[»]
3BJIX-ray2.60A/B189-565[»]
SMRP15498. Positions 1-135, 169-375, 644-780.
ModBaseSearch...

Protein-protein interaction databases

DIPDIP:1061N.
IntActP15498. 3 interactions.

PTM databases

PhosphoSiteP15498.

Proteomic databases

PeptideAtlasP15498.
PRIDEP15498.

Genome annotation databases

EnsemblENSG00000141968. Homo sapiens. [Contig view]
GeneID7409.
KEGGhsa:7409.

Organism-specific databases

GeneCardsGC19P006723.
H-InvDBHIX0014706.
HGNCHGNC:12657. VAV1.
HPAHPA001864.
MIM164875. gene.
PharmGKBPA37280.
GenAtlasSearch...

Phylogenomic databases

HOGENOMP15498.
HOVERGENP15498.
OMAP15498. ANRSDGT.

Enzyme and pathway databases

Pathway_Interaction_DBpi3kcipathway. Class I PI3K signaling events.
fcer1pathway. Fc-epsilon receptor I signaling in mast cells.
il6_7pathway. IL6-mediated signaling events.
kitpathway. Signaling events mediated by Stem cell factor receptor (c-Kit).
tcrpathway. TCR signaling in naive CD4+ T cells.
cd8tcrpathway. TCR signaling in naive CD8+ T cells.
ReactomeREACT_11044. Signaling by Rho GTPases.

Gene expression databases

ArrayExpressP15498.
BgeeP15498.
CleanExHS_VAV1.

Family and domain databases

InterProIPR001715. Calponin_act_bd.
IPR002219. DAG_PE_bd.
IPR000219. DH-domain.
IPR001331. GDS_CDC24_CS.
IPR001849. Pleckstrin_homology.
IPR000980. SH2.
IPR001452. SH3_domain.
IPR003096. SM22_calponin.
[Graphical view]
Gene3DG3DSA:1.10.418.10. Calponin-homology. 1 hit.
G3DSA:1.20.900.10. RhoGEF. 1 hit.
G3DSA:3.30.505.10. SH2. 1 hit.
PfamPF00130. C1_1. 1 hit.
PF00307. CH. 1 hit.
PF00169. PH. 1 hit.
PF00621. RhoGEF. 1 hit.
PF00017. SH2. 1 hit.
PF00018. SH3_1. 2 hits.
[Graphical view]
PRINTSPR00401. SH2DOMAIN.
PR00888. SM22CALPONIN.
ProDomPD000093. SH2. 1 hit.
PD000066. SH3. 1 hit.
[Graphical view] [Entries sharing at least one domain]
SMARTSM00109. C1. 1 hit.
SM00033. CH. 1 hit.
SM00233. PH. 1 hit.
SM00325. RhoGEF. 1 hit.
SM00252. SH2. 1 hit.
SM00326. SH3. 2 hits.
[Graphical view]
PROSITEPS50021. CH. 1 hit.
PS00741. DH_1. 1 hit.
PS50010. DH_2. 1 hit.
PS50003. PH_DOMAIN. 1 hit.
PS50001. SH2. 1 hit.
PS50002. SH3. 2 hits.
PS00479. ZF_DAG_PE_1. 1 hit.
PS50081. ZF_DAG_PE_2. 1 hit.
[Graphical view]
ProtoNetSearch...

Other Resources

NextBio29008.
PMAP-CutDBP15498.
SOURCESearch...

Entry information

Entry nameVAV_HUMAN
AccessionPrimary (citable) accession number: P15498
Secondary accession number(s): Q15860
Entry history
Integrated into UniProtKB/Swiss-Prot: April 1, 1990
Last sequence update: February 21, 2001
Last modified: June 16, 2009
This is version 119 of the entry and version 4 of the sequence. [Complete history]
Entry statusReviewed (UniProtKB/Swiss-Prot)
Annotation projectHPI (Human Proteome Initiative)

Relevant documents

Human chromosome 19

Human chromosome 19: entries, gene names and cross-references to MIM

Human entries with polymorphisms or disease mutations

List of human entries with polymorphisms or disease mutations

Human polymorphisms and disease mutations

Index of human polymorphisms and disease mutations

MIM cross-references

Online Mendelian Inheritance in Man (MIM) cross-references in UniProtKB/Swiss-Prot

PDB cross-references

Index of Protein Data Bank (PDB) cross-references

SIMILARITY comments

Index of protein domains and families

Names and origin · Protein attributes · General annotation (Comments) · Ontologies · Binary interactions · Sequence annotation (Features) · Sequences · References · Web resources · Cross-references · Entry information · Relevant documents